<DOC>
	<DOCNO>NCT01526356</DOCNO>
	<brief_summary>The study multi-center prospective , randomize , double-blind , placebo-controlled evaluation safety efficacy topically apply formulation rapamycin cutaneous angiofibromas subject Tuberous Sclerosis Complex ( TSC ) . Subjects apply either topical vehicle contain rapamycin topical vehicle alone nightly angiofibromas six month . The primary goal study evaluate efficacy topical medication reduction cutaneous angiofibromas patient TSC . The secondary goal study confirm safety topical medication .</brief_summary>
	<brief_title>Topical Rapamycin Erase Angiofibromas TSC</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Angiofibroma</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects must willing able comply trial requirement . Subject diagnosis TSC visible facial angiofibromas . Female subject child bear potential must pregnant must agree use appropriate contraceptive method . Subject currently receive therapy Rapamycin . Subject receive form immunosuppression previously experience immune dysfunction . Subject currently participate participate within last 30 day clinical trial involve investigational drug . Subject know hypersensitivity either vehicle Rapamycin . Subject pregnant nursing female . Subject dermatologic condition would preclude prevent adequate assessment change facial angiofibromas . Subject laser surgery , cryotherapy , dermatologic treatment facial angiofibromas within previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Angiofibroma</keyword>
	<keyword>Tuberous Sclerosis</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>mTOR</keyword>
</DOC>